ALLE,MRK Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Dollar change +1.07
Percentage change 0.75	%

Peers: MAS JCI MMM AAON AOS AYI DHR IR HON

| Held by: MOAT VTI VOO VB VBR SPY IVV RSP XHB VIG

Index	S&P 500	P/E	22.08	EPS (ttm)	6.51	Insider Own	0.30%	Shs Outstand	87.50M	Perf Week	2.82%
Market Cap	12.59B	Forward P/E	18.45	EPS next Y	7.79	Insider Trans	-1.58%	Shs Float	86.66M	Perf Month	-0.59%
Income	572.00M	PEG	2.65	EPS next Q	1.75	Inst Own	97.59%	Short Float	2.33%	Perf Quarter	11.67%
Sales	3.72B	P/S	3.38	EPS this Y	6.36%	Inst Trans	0.47%	Short Ratio	2.73	Perf Half Y	14.12%
Book/sh	18.07	P/B	7.96	EPS next Y	5.29%	ROA	12.49%	Short Interest	2.02M	Perf Year	40.86%
Cash/sh	10.04	P/C	14.33	EPS next 5Y	8.33%	ROE	40.81%	52W Range	101.11 - 156.10	Perf YTD	13.49%
Dividend Est.	1.91 (1.33%)	P/FCF	21.59	EPS past 5Y	5.98%	ROI	15.57%	52W High	-7.89%	Beta	1.12
Dividend TTM	1.89 (1.31%)	Quick Ratio	1.29	Sales past 5Y	6.18%	Gross Margin	43.98%	52W Low	42.20%	ATR (14)	2.97
Dividend Ex-Date	Sep 20, 2024	Current Ratio	1.71	EPS Y/Y TTM	3.28%	Oper. Margin	20.82%	RSI (14)	50.99	Volatility	2.16% 1.93%
Employees	12400	Debt/Eq	1.63	Sales Y/Y TTM	3.02%	Profit Margin	15.36%	Recom	2.75	Target Price	147.38
Option/Short	Yes / Yes	LT Debt/Eq	1.34	EPS Q/Q	12.22%	Payout	29.41%	Rel Volume	0.88	Prev Close	142.71
Sales Surprise	-0.36%	EPS Surprise	8.90%	Sales Q/Q	5.36%	Earnings	Oct 24 BMO	Avg Volume	738.14K	Price	143.78
SMA20	-1.03%	SMA50	0.32%	SMA200	9.84%	Trades		Volume	650,944	Change	0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-24	Downgrade	Barclays	Equal Weight → Underweight	$122 → $116
Feb-23-24	Downgrade	Mizuho	Buy → Neutral	$140 → $141
Feb-21-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$139 → $140
Dec-04-23	Downgrade	Barclays	Overweight → Equal Weight	$130 → $119
Oct-19-23	Downgrade	Vertical Research	Buy → Hold	$128 → $100
Sep-06-23	Downgrade	Longbow	Buy → Neutral
Jan-03-23	Upgrade	Vertical Research	Hold → Buy	$128
Jul-11-22	Downgrade	BofA Securities	Neutral → Underperform	$110
Feb-16-22	Reiterated	Wells Fargo	Overweight	$157 → $147
Feb-16-22	Reiterated	Morgan Stanley	Equal-Weight	$146 → $134
Feb-16-22	Reiterated	Mizuho	Buy	$170 → $145
Feb-16-22	Reiterated	Credit Suisse	Neutral	$142 → $134
Dec-17-21	Initiated	Mizuho	Buy	$170
Dec-08-21	Downgrade	BofA Securities	Buy → Neutral	$163 → $142
Nov-29-21	Initiated	Atlantic Equities	Overweight	$155
Oct-08-21	Initiated	Wells Fargo	Overweight	$159
Sep-10-21	Upgrade	Goldman	Neutral → Buy	$158 → $174
Apr-06-21	Upgrade	Barclays	Underweight → Overweight	$107 → $150
Mar-16-21	Upgrade	Longbow	Neutral → Buy
Nov-11-20	Upgrade	BofA Securities	Neutral → Buy	$128

Show Previous Ratings

Nov-07-24 04:41AM	3 No-Brainer Long-Term Growth Stocks to Buy Right Now (Motley Fool)
Nov-04-24 04:00PM	Students Tour Allegion's Technical Glass Products Operations in Snoqualmie for 2024 MFG Day Field Trip (PR Newswire)
Nov-01-24 09:40AM	Why Allegion (ALLE) is a Top Value Stock for the Long-Term (Zacks)
Oct-30-24 05:00PM	Allegion to Attend 2024 Baird Global Industrial Conference (Business Wire)
Oct-29-24 03:18PM	Powell (NASDAQ:POWL) Q2 Earnings: Leading The Electrical Systems Pack (StockStory)
03:08AM	Loading…
Oct-25-24 03:08AM	Allegion PLC (ALLE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:04AM	Decoding Allegion PLC (ALLE): A Strategic SWOT Insight (GuruFocus.com)
Oct-24-24 01:53PM	Analyst Report: Allegion plc (Morningstar Research)
07:05AM	Allegion (ALLE) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:55AM	Allegion Plc Raises Full-year Adj. EPS Guidance - Update (RTT News)
05:50AM	Allegion: Q3 Earnings Snapshot (Associated Press Finance)
05:42AM	Allegion (NYSE:ALLE) Posts Q3 Sales In Line With Estimates (StockStory)
05:30AM	Allegion (NYSE: ALLE) Reports Q3-2024 Financial Results (Business Wire)
Oct-23-24 03:08AM	Allegion (ALLE) Q3 Earnings: What To Expect (StockStory)
Oct-18-24 07:00AM	Allegion Acquires SOSS Door Hardware, Adding Another Category Leader to Its Safety and Security Portfolio (Business Wire)
09:40AM	Loading…
Oct-17-24 09:40AM	Are Industrial Products Stocks Lagging Allegion (ALLE) This Year? (Zacks)
Oct-14-24 05:00AM	Electrical Systems Stocks Q2 Teardown: Whirlpool (NYSE:WHR) Vs The Rest (StockStory)
Oct-10-24 05:00PM	Allegion Schedules Conference Call, Webcast to Announce 2024 Third-Quarter Results (Business Wire)
Oct-09-24 09:15AM	Allegion PLC (ALLE) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-08-24 09:45AM	Here's Why Allegion (ALLE) is a Strong Growth Stock (Zacks)
Oct-01-24 02:00PM	Technical Glass Products Bolsters Project Support with New Architectural Services Manager (PR Newswire)
09:40AM	Is Allegion (ALLE) Stock Outpacing Its Industrial Products Peers This Year? (Zacks)
Sep-23-24 09:50AM	Why Allegion (ALLE) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-18-24 09:15AM	Allegion PLC (ALLE) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-17-24 02:00PM	Air Louvers Expands Fire Door Options with Fire-Rated Products from TGP (PR Newswire)
Sep-16-24 08:00AM	Allegion Board of Directors Elects Lauren B. Peters as Chair (Business Wire)
Sep-13-24 06:31PM	Analyst Report: Allegion plc (Morningstar Research)
Sep-12-24 09:45AM	Why Allegion (ALLE) is a Top Growth Stock for the Long-Term (Zacks)
09:40AM	Is Allegion (ALLE) Outperforming Other Industrial Products Stocks This Year? (Zacks)
Sep-09-24 03:42AM	Q2 Rundown: Allegion (NYSE:ALLE) Vs Other Electrical Systems Stocks (StockStory)
05:10PM	Loading…
Sep-05-24 05:10PM	Allegion Declares Quarterly Dividend (Business Wire)
Aug-27-24 09:40AM	Has Allegion (ALLE) Outpaced Other Industrial Products Stocks This Year? (Zacks)
Aug-23-24 11:30AM	Allegion (ALLE) Up 1.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-19-24 09:55AM	Allegion (ALLE)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-14-24 12:36PM	Here's Why You Should Add Allegion (ALLE) to Your Portfolio (Zacks)
Aug-08-24 09:00AM	Allegion Announces Pure Access Cloud Integration with TagMaster North America RFID Reader To Enhance Safety & Convenience for Customers (PR Newswire)
Aug-06-24 08:36AM	Implied Volatility Surging for Allegion (ALLE) Stock Options (Zacks)
Aug-05-24 03:07AM	Earnings To Watch: Atkore (ATKR) Reports Q2 Results Tomorrow (StockStory)
Jul-31-24 05:00PM	Allegion Releases 2023 ESG Metrics, Digital Annual Report (Business Wire)
Jul-30-24 07:01PM	Insider Buying: Allegion PLC President and CEO Acquires Shares (GuruFocus.com)
07:00PM	Director Steven Mizell Acquires 1,000 Shares of Allegion PLC (ALLE) (GuruFocus.com)
09:40AM	Are Industrial Products Stocks Lagging Allegion (ALLE) This Year? (Zacks)
Jul-29-24 09:15AM	Allegion PLC (ALLE) Soars to 52-Week High, Time to Cash Out? (Zacks)
03:03AM	Earnings To Watch: Hubbell (HUBB) Reports Q2 Results Tomorrow (StockStory)
Jul-26-24 02:43PM	Allegion Stock Earns RS Rating Upgrade (Investor's Business Daily)
Jul-25-24 01:03AM	Decoding Allegion PLC (ALLE): A Strategic SWOT Insight (GuruFocus.com)
Jul-24-24 03:45PM	Analyst Report: Allegion plc (Morningstar Research)
11:40AM	Allegion (ALLE) Q2 Earnings Top Estimates, Revenues Up Y/Y (Zacks)
07:05AM	Allegion (ALLE) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:08AM	Allegion Raises Full-year Adj. EPS Outlook (RTT News)
05:41AM	Allegion (NYSE:ALLE) Surprises With Q2 Sales (StockStory)
05:35AM	Allegion: Q2 Earnings Snapshot (Associated Press Finance)
05:30AM	Allegion (NYSE: ALLE) Reports Q2-2024 Financial Results (Business Wire)
Jul-23-24 03:07AM	Allegion (ALLE) Reports Earnings Tomorrow: What To Expect (StockStory)
Jul-19-24 10:56AM	Allegion (ALLE) to Report Q2 Earnings: What's in the Offing? (Zacks)
03:43AM	Q1 Earnings Highlights: Allegion (NYSE:ALLE) Vs The Rest Of The Electrical Systems Stocks (StockStory)
Jul-17-24 10:01AM	Allegion (ALLE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-24 04:24AM	Q1 Earnings Highlights: Identiv (NASDAQ:INVE) Vs The Rest Of The Electrical Systems Stocks (StockStory)
Jul-09-24 05:30PM	Allegion Schedules Conference Call, Webcast to Announce 2024 Second-Quarter Results (Business Wire)
12:10PM	Will Allegion (ALLE) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-01-24 08:00AM	Allegion Appoints Stacy Cozad as New General Counsel (Business Wire)
Jun-28-24 12:16PM	Here's Why Investors Should Bet on Allegion (ALLE) Stock Now (Zacks)
07:30AM	Old Dominion University Launches Mobile Credentials with CBORD and Allegion (GlobeNewswire)
Jun-25-24 09:00AM	Allegion Introduces the Von Duprin 70 Series Exit Devices, Offering New Level of Quality at Mid-Price Point (PR Newswire)
Jun-23-24 06:33PM	3 Smart Stocks to Buy and Hold for the Long Term With $500 Right Now (Motley Fool)
Jun-21-24 03:52PM	Analyst Report: Allegion plc (Morningstar Research)
Jun-20-24 02:04PM	Top 20 Smart Home Companies Revolutionizing the US (Insider Monkey)
Jun-19-24 08:00AM	Zentra Brings Resident Keys in Apple Wallet to Customers (PR Newswire)
Jun-18-24 09:00AM	University of Notre Dame Launches Mobile Credentials with CBORD (GlobeNewswire)
Jun-12-24 10:57AM	Allegion (ALLE) Enhances Product Portfolio With Unicel Buyout (Zacks)
Jun-11-24 07:30AM	Allegion Acquires Unicel Architectural, Growing Core Business & Specification Capabilities (Business Wire)
Jun-05-24 12:12PM	Allegion (ALLE) Boosts Product Portfolio With Krieger Buyout (Zacks)
Jun-04-24 07:00AM	Allegion Acquires Krieger Specialty Products, Expanding Allegion Americas Institutional Market Portfolio (Business Wire)
May-30-24 11:33AM	Allegion (ALLE) Unveils Schlage XE360 Series Wireless Locks (Zacks)
May-29-24 09:30AM	Allegion Launches Schlage XE360(TM) Series Wireless Locks for Multifamily Applications (Newsfile)
May-28-24 01:00PM	Here's Why Investing in Allegion (ALLE) Stock Makes Sense Now (Zacks)
May-22-24 05:00PM	Allegion to Attend 2024 KeyBanc Capital Markets Industrials & Basic Materials Conference (Business Wire)
May-21-24 07:45PM	Allegion Announces Pricing of $400 Million of Senior Notes (Business Wire)
May-20-24 04:51PM	Allegion Extends, Upsizes Revolving Credit Facility (MT Newswires)
04:15PM	Allegion Completes Extension and Increase of Revolving Credit Facility (Business Wire)
May-15-24 09:30AM	Allegion Expands Indication Trim Portfolio, Launches Patented Schlage Solutions for K12, Higher Education, Healthcare and Privacy Applications (Newsfile)
May-14-24 12:00PM	All You Need to Know About Allegion (ALLE) Rating Upgrade to Buy (Zacks)
May-08-24 04:30PM	Allegiant Travel Company (NASDAQ:ALGT) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-30-24 11:50AM	Allegion plc (NYSE:ALLE) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-26-24 05:12PM	Analyst Report: Allegion plc (Morningstar Research)
01:26PM	Improved Stanley Dura-Storm Hurricane/Storm Door Set to Exceed Safety Standards in Coastal Regions (PR Newswire)
11:32AM	Goldman Sachs Adjusts Price Target on Allegion to $142 From $141 (MT Newswires)
09:25AM	Allegion (ALLE) Q1 Earnings Top Estimates, Sales Down Y/Y (Zacks)
07:33AM	Baird Adjusts Allegion Price Target to $145 From $146 (MT Newswires)
01:05AM	Decoding Allegion PLC (ALLE): A Strategic SWOT Insight (GuruFocus.com)
Apr-25-24 11:21AM	Analyst Report: Allegion plc (Morningstar Research)
09:59AM	Allegion Shares Decline Following Lower Q1 Adjusted Earnings, Revenue (MT Newswires)
09:52AM	ALLE Stock Earnings: Allegion Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:42AM	Allegion beats quarterly profit estimates on strong demand for security devices (Reuters)
07:34AM	Allegion PLC Q1 Earnings: Navigates Market Challenges, Aligns Closely with Analyst Projections (GuruFocus.com)
07:05AM	Allegion (ALLE) Q1 Earnings Surpass Estimates (Zacks)
06:03AM	Allegion Q1 Net Income Increases; Affirms 2024 Outlook - Quick Facts (RTT News)
05:40AM	Allegion: Q1 Earnings Snapshot (Associated Press Finance)
05:30AM	Allegion (NYSE: ALLE) Reports Q1-2024 Financial Results (Business Wire)
Apr-23-24 10:03AM	What's in the Offing for Allegion (ALLE) This Earnings Season? (Zacks)

Allegion Plc engages in the provision of security products and solutions that keep people safe, secure, and productive. It operates through the Allegion Americas and Allegion International segments. The Allegion Americas segment offers security products, services, and solutions throughout North America. The Allegion International segment refers to security products, services, and solutions primarily throughout Europe, Asia and Oceania. The company was founded on May 9, 2013 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martens Robert C.	SVP Chief Innovation & Design	Oct 25 '24	Option Exercise	121.67	8,035	977,628	15,139	Oct 29 05:08 PM
Martens Robert C.	SVP Chief Innovation & Design	Oct 25 '24	Sale	144.92	8,035	1,164,432	7,104	Oct 29 05:08 PM
Robert Martens	Officer	Oct 25 '24	Proposed Sale	145.27	8,035	1,167,244		Oct 25 04:41 PM
Jeffrey Braun	Senior Vice President Advisory	Aug 05 '24	Proposed Sale	126.87	7,675	973,737		Aug 05 05:58 PM
Stone John H	President and CEO	Jul 26 '24	Buy	134.99	5,000	674,925	118,640	Jul 30 04:23 PM
MIZELL STEVEN	Director	Jul 26 '24	Buy	136.53	1,000	136,530	5,545	Jul 30 04:20 PM
Kemp Tracy L	SVP-Chief Info. & Digital Ofr.	May 28 '24	Sale	121.98	2,194	267,629	11,103	May 30 04:34 PM
Eckersley Timothy P	Sr. VP-Allegion International	Mar 11 '24	Option Exercise	71.83	5,047	362,551	40,614	Mar 12 07:59 PM
Eckersley Timothy P	Sr. VP-Allegion International	Mar 11 '24	Sale	130.63	5,089	664,799	0	Mar 12 07:59 PM
Eckersley Timothy P	Sr. VP-Allegion International	Mar 11 '24	Sale	129.99	5,047	656,060	35,567	Mar 12 07:59 PM
Eckersley Timothy P	Sr. VP-Allegion International	Mar 12 '24	Sale	132.75	2,291	304,130	33,276	Mar 12 07:59 PM
Stone John H	President and CEO	Feb 22 '24	Buy	132.41	10,000	1,324,146	104,248	Feb 26 08:23 PM
Martens Robert C.	SVP Chief Innovation & Design	Feb 22 '24	Option Exercise	106.64	5,391	574,893	12,946	Feb 26 08:16 PM
Martens Robert C.	SVP Chief Innovation & Design	Feb 22 '24	Sale	132.84	5,391	716,162	7,555	Feb 26 08:16 PM
Braun Jeffrey N	SVP and GC	Feb 21 '24	Sale	131.00	3,000	393,000	9,653	Feb 22 04:18 PM
Eckersley Timothy P	Sr. VP-Allegion International	Dec 15 '23	Sale	118.00	6,103	720,159	36,166	Dec 19 04:17 PM
Martens Robert C.	SVP Chief Innovation & Design	Dec 08 '23	Sale	110.52	4,068	449,605	6,714	Dec 12 05:12 PM

Dollar change +1.75
Percentage change 1.73	%

Peers: PFE JNJ ABBV BMY AMGN LLY REGN GILD VRTX BHC

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM VHT IWF

Index	DJIA, S&P 500	P/E	21.56	EPS (ttm)	4.77	Insider Own	0.10%	Shs Outstand	2.53B	Perf Week	1.02%
Market Cap	264.85B	Forward P/E	10.94	EPS next Y	9.41	Insider Trans	0.00%	Shs Float	2.53B	Perf Month	-5.92%
Income	12.15B	PEG	0.90	EPS next Q	1.85	Inst Own	79.07%	Short Float	1.03%	Perf Quarter	-9.31%
Sales	62.89B	P/S	4.21	EPS this Y	412.98%	Inst Trans	1.12%	Short Ratio	2.84	Perf Half Y	-20.87%
Book/sh	17.58	P/B	5.86	EPS next Y	21.45%	ROA	10.83%	Short Interest	26.04M	Perf Year	-1.42%
Cash/sh	5.69	P/C	18.10	EPS next 5Y	23.85%	ROE	28.33%	52W Range	98.60 - 134.63	Perf YTD	-5.60%
Dividend Est.	3.05 (2.96%)	P/FCF	17.85	EPS past 5Y	-42.70%	ROI	15.28%	52W High	-23.55%	Beta	0.41
Dividend TTM	3.08 (2.99%)	Quick Ratio	1.15	Sales past 5Y	7.72%	Gross Margin	73.03%	52W Low	4.38%	ATR (14)	1.97
Dividend Ex-Date	Sep 16, 2024	Current Ratio	1.36	EPS Y/Y TTM	163.70%	Oper. Margin	23.00%	RSI (14)	36.62	Volatility	1.69% 1.74%
Employees	72000	Debt/Eq	0.86	Sales Y/Y TTM	8.17%	Profit Margin	19.32%	Recom	1.58	Target Price	131.16
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	-33.34%	Payout	2065.60%	Rel Volume	1.00	Prev Close	101.17
Sales Surprise	1.11%	EPS Surprise	5.80%	Sales Q/Q	4.42%	Earnings	Oct 31 BMO	Avg Volume	9.17M	Price	102.92
SMA20	-2.20%	SMA50	-7.06%	SMA200	-15.39%	Trades		Volume	9,206,567	Change	1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93

Show Previous Ratings

Nov-09-24 10:41AM	Merck & Co., Inc. (MRK): Among the Best Low Volatility Stocks to Invest In Now (Insider Monkey)
Nov-08-24 02:47PM	Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement (PR Newswire)
11:23AM	Why WEC Energy, Merck And Regions Financial Are Winners For Passive Income (Benzinga)
09:36AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
10:36AM	Loading…
Nov-07-24 10:36AM	Merck & Co., Inc. (MRK) Makes It On UBS List Of Stocks For The AI, Growth & Low Rates Era (Insider Monkey)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-06-24 06:45AM	Merck to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-04-24 06:41PM	Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now? (Insider Monkey)
Nov-01-24 02:33PM	Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease (Benzinga)
03:08AM	Merck & Co Inc (MRK) Q3 2024 Earnings Call Highlights: Strong Oncology and Animal Health ... (GuruFocus.com)
01:55AM	Q3 2024 Merck & Co Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-31-24 04:12PM	Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales (Investor's Business Daily)
02:03PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
01:15PM	Merck (MRK) Q3 2024 Earnings Call Transcript (Motley Fool)
10:03AM	Loading…
10:03AM	Bristol Myers Squibb stock rises, Merck moves lower. Here's why. (Yahoo Finance Video)
07:09AM	Merck earnings top estimates amid solid demand for Keytruda cancer drug (Investing.com)
06:37AM	Merck: Q3 Earnings Snapshot (Associated Press Finance)
06:35AM	Merck sees Gardasil China woes carrying into 2025 (Reuters)
06:30AM	Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses? (Investor's Business Daily)
06:30AM	Merck Announces Third-Quarter 2024 Financial Results (Business Wire)
Oct-30-24 12:44PM	Merck & Co., Inc. (MRK): A Bull Case Theory (Insider Monkey)
01:29AM	Jim Cramer Thinks That Merck & Co., Inc. (MRK) Is Too Low (Insider Monkey)
Oct-28-24 12:45PM	Why Is Moderna Stock Trading Higher On Monday? (Benzinga)
06:45AM	Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Oct-27-24 08:58AM	Merck & Co., Inc. (MRK): Among the Best Dow Stocks to Buy According to Analysts (Insider Monkey)
01:39AM	Merck & Co., Inc. (MRK): Among the Best Stocks to Buy for High Returns in 2024 (Insider Monkey)
Oct-25-24 06:47PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
04:15PM	BetterInvesting Magazine Update on Merck (MRK) and Ball (BALL) (PR Newswire)
Oct-24-24 02:46PM	CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines (Benzinga)
01:42PM	Loading…
01:42PM	US CDC AdCom recommends lowering the age for pneumococcal vaccines (Pharmaceutical Technology)
01:25PM	Merck (MRK): Patent Concerns and Earnings Forecast Cuts Impact Dow Performance (Insider Monkey)
10:01AM	Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:00AM	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:45AM	Mercks KEYTRUDA (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers (Business Wire)
Oct-23-24 07:58PM	CDCS ACIP Recommends Mercks CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older (Business Wire)
03:35PM	800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio (Benzinga)
10:06AM	Is Merck & Co., Inc. (NYSE:MRK) the Most Undervalued Value Stock to Buy According to Analysts? (Insider Monkey)
07:45AM	Merck acquires cancer drug startup; Elevidys ex-US sales rise (BioPharma Dive)
Oct-22-24 05:50PM	Merck (MRK) Advances While Market Declines: Some Information for Investors (Zacks)
Oct-21-24 12:28PM	Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks (Benzinga)
Oct-20-24 03:00PM	Merck & Co. Inc. (MRK): Among the Best US Stocks for Foreign Investors Right Now (Insider Monkey)
Oct-19-24 05:09PM	Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 (Business Wire)
11:57AM	Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE (Insider Monkey)
Oct-18-24 04:46PM	MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win (Pharmaceutical Technology)
03:25PM	Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals (Insider Monkey)
08:08AM	Merck antibody reduces RSV-related disease, hospitalizations in trial (BioPharma Dive)
03:20AM	Merck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios (Insider Monkey)
Oct-17-24 06:34PM	Is Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds? (Insider Monkey)
06:00PM	Mercks Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants (Business Wire)
01:41PM	Merck (MRK): Promising Long-Term Stock with Strategic Acquisitions (Insider Monkey)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
06:45AM	Mercks CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease (Business Wire)
02:00AM	Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical Officer (GlobeNewswire)
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily)
05:50PM	Merck (MRK) Rises As Market Takes a Dip: Key Facts (Zacks)
Oct-14-24 08:27AM	erck & Co. (MRK): Winrevair Approval Drives Cardiovascular Growth (Insider Monkey)
08:00AM	Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma (Business Wire)
Oct-12-24 12:37PM	Is Merck & Co. Inc. (MRK) The Most Undervalued Quality Stock To Buy According To Analysts? (Insider Monkey)
Oct-11-24 09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:38AM	Should You Invest in Merck & Co. (MRK)? (Insider Monkey)
Oct-10-24 10:57AM	Is Merck & Co Inc. (MRK) the Best Quality Stock to Buy According to Analysts? (Insider Monkey)
Oct-09-24 11:21AM	MSD ventures into fibroblast therapies with $1.9bn deal with Mestag (Pharmaceutical Technology)
06:45AM	New Data to be Presented at IDWeek 2024 Reinforce Mercks Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio (Business Wire)
05:30AM	MSDs Phase III trial of head and neck cancer treatment meets primary endpoint (Clinical Trials Arena)
Oct-08-24 03:44PM	Merck & Co., Inc. (MRK) is One of The Best Cheap Stocks to Buy According to Billionaire Ray Dalio (Insider Monkey)
06:45AM	Mercks KEYTRUDA (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma (Business Wire)
Oct-07-24 06:33AM	Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial (Clinical Trials Arena)
Oct-06-24 03:36PM	Merck & Co Inc. (MRK): Analysts Are Bullish On This Quality Stock Right Now (Insider Monkey)
Oct-04-24 09:40AM	Career on Purpose (Episode 1): Merck's Skills-First Program (ACCESSWIRE)
Oct-03-24 08:30AM	Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. (Investor's Business Daily)
08:30AM	Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More (PR Newswire)
Oct-01-24 06:45AM	Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (Business Wire)
06:30AM	Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31 (Business Wire)
Sep-30-24 12:30PM	Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth (Insider Monkey)
04:50AM	Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth (Insider Monkey)
Sep-29-24 06:28AM	Is Merck Stock a Buy? (Motley Fool)
Sep-27-24 12:09PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
06:38AM	Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts (Insider Monkey)
Sep-26-24 12:23PM	Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In? (Insider Monkey)
06:45AM	Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024 (Business Wire)
04:27AM	Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts (Insider Monkey)
Sep-25-24 03:54PM	FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients (Benzinga)
08:32AM	Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study (Benzinga)
06:45AM	Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer (Business Wire)
06:30AM	Mercks KEYTRUDA (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma (Business Wire)
12:11AM	Merck & Co., Inc. (MRK) Poised for 20% Gain, Analysts Say (Insider Monkey)
Sep-24-24 08:06AM	Merck Animal Health Announces Expansion of NOBIVAC NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus (Business Wire)
Sep-20-24 10:48AM	Pfizer Advances On Its Cancer Journey (Benzinga)
09:00AM	How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs (GlobeNewswire)
07:30AM	Merck Receives Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers (Business Wire)
Sep-19-24 09:00AM	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know (Zacks)
Sep-18-24 02:45PM	Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer (Benzinga)
06:45AM	FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) (Business Wire)
04:52AM	Daiichi Sankyo and MSDs ADC improves progression-free survival in NSCLC trial (Clinical Trials Arena)
Sep-17-24 07:58AM	Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study (Benzinga)
07:51AM	ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial (BioPharma Dive)
06:00AM	Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial (Business Wire)
Sep-16-24 07:00AM	BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 (GlobeNewswire)
Sep-15-24 10:30AM	KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) (Business Wire)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM
Smart Dalton	SVP Fin. - Global Controller	May 03 '24	Option Exercise	128.26	2,046	262,420	4,708	May 06 04:10 PM
Smart Dalton	SVP Fin. - Global Controller	May 04 '24	Option Exercise	127.51	612	78,036	4,730	May 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 04 '24	Option Exercise	127.51	27,126	3,458,836	163,720	May 06 04:08 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04 '24	Option Exercise	127.51	887	113,101	24,058	May 06 04:06 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04 '24	Option Exercise	127.51	912	116,289	24,271	May 06 04:01 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '24	Option Exercise	128.80	2,262	291,346	21,831	May 02 04:29 PM
Smart Dalton	SVP Fin. - Global Controller	May 02 '24	Option Exercise	128.80	381	49,073	3,048	May 02 04:23 PM
Merck & Co., Inc.	10% Owner	Mar 11 '24	Buy	23.00	21,397,205	492,135,715	1,000	Mar 11 03:27 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Option Exercise	58.08	38,291	2,223,941	89,199	Feb 15 04:03 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Sale	125.50	38,291	4,805,520	50,908	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Option Exercise	74.18	150,000	11,127,160	498,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Option Exercise	73.73	85,021	6,268,598	433,348	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Sale	125.85	150,000	18,877,424	348,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Sale	125.40	85,021	10,661,574	348,327	Feb 15 04:01 PM
Romanelli Joseph	President, Human Health Int?l	Feb 13 '24	Sale	124.89	1,000	124,888	19,569	Feb 14 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Option Exercise	62.07	14,702	912,553	60,944	Feb 12 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Sale	125.50	14,702	1,845,083	46,242	Feb 12 04:03 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 07 '24	Sale	127.57	1,451	185,108	19,812	Feb 08 04:04 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Option Exercise	78.80	20,937	1,649,906	42,286	Feb 05 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Sale	127.17	18,959	2,411,111	23,327	Feb 05 04:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Option Exercise	73.65	32,994	2,430,159	74,313	Feb 02 04:07 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Sale	126.65	50,694	6,420,349	23,619	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Option Exercise	87.10	19,417	1,691,221	78,557	Feb 02 04:05 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Sale	126.97	49,499	6,284,779	29,058	Feb 02 04:05 PM

ALLE

Allegion plc

MRK

Merck & Co Inc

Upgrade your FINVIZ experience